Eight people worked at CytomX when Nancy Stagliano described what the company would do with its new money. The plan was to add about ten colleagues and move from Santa Barbara to the San Francisco Bay Area. It was 2010. The financing was $30 million. For a moment, the arithmetic of building a company was wonderfully plain: more people, a different address, and enough money to begin the next chapter.
The move had a practical explanation. Stagliano wanted proximity to investors and access to an established pool of talent. People changed companies, she observed, but the industry’s workers tended to cluster around San Francisco and Boston. Santa Barbara offered many attractions. A ready supply of experienced biotech hires was the attraction she needed next. The decision to move north put the company closer to both its backers and the people it hoped to recruit.
It is a useful place to begin with Stagliano. Her career can be told through appointments and acquisitions, but this small company moment puts the work at a human scale. Eight employees become a hiring plan. An idea becomes an organization. A founder has to decide where the next people will come from.
Before the boardroom, three disciplines
Stagliano’s education began in engineering. She earned a bachelor’s degree in electrical engineering and a master’s in biomedical engineering at Drexel University in Philadelphia. A doctorate in neuroscience at the University of Miami followed. The sequence crosses three disciplines before the first chief executive title appears. It also gives her professional history an unusually concrete starting point: learning how systems work, then taking those questions into another field.
At Miami, she trained in W. Dalton Dietrich’s laboratory and completed her Ph.D. in 1996. Years later, Dietrich remembered that she was already thinking beyond the laboratory bench. Her own account emphasizes collaboration and an education that brought different disciplines together. Those are features of a working environment, as well as a curriculum. They help explain why the later story contains so many teams and partnerships. Her Miami years were an early chapter in that collaborative approach.
She then spent three years as an independently funded research fellow at Massachusetts General Hospital and Harvard Medical School. The move placed another institution, and another kind of research setting, between her doctorate and industry. By the late 1990s, she had entered the biotechnology business in Cambridge, Massachusetts. The educational route was winding; the progression from training to applied work was clear. Her early professional biography records the degrees, fellowship, and move into industry.
The management lesson arrived with the job
During Drexel’s co-op program, Stagliano had worked in several environments, including IBM and an assembly line. These experiences helped her consider the sort of workplace she wanted. Later, at Millennium Pharmaceuticals, responsibility arrived before she felt prepared for management. She recalled having to learn how to manage people, report progress, and plan group projects. It is a candid detail in a career often reduced to a list of CEO positions. Her account of that transition includes the uncertainty as well as the opportunity.
She stayed at Millennium for roughly eight years and also consulted for local startups. Her experience extended across research, strategy, and corporate communications. By the time she moved to California, her work already involved several sides of an organization. A scientific career had acquired the practical demands of coordinating a business. The Millennium chapter preceded her work launching companies on the West Coast.
A founder with her name on the invention
CytomX was founded in 2008 around technology licensed from the University of California, Santa Barbara. Stagliano’s fellow founders included Patrick Daugherty, a professor of chemical engineering, and Frederick Gluck, the former managing partner of McKinsey. Their backgrounds brought academic research, corporate leadership, and biotechnology experience into the same venture. Stagliano served as chief executive. The company’s 2010 financing announcement names all three founders.
Her connection to the company also extended to its intellectual property. She was a co-inventor of its foundational platform. That distinction matters in a profile of a scientific executive: the company’s early story contains her contribution to the invention alongside her responsibility for the organization. The later CEO succession announcement would explicitly acknowledge both. Her work with CytomX LLC had also involved the launch of Cynvenio Biosystems, giving this period more than one company-building thread. Her subsequent iPierian biography describes those earlier operating responsibilities.
Third Rock Ventures led the $30 million Series B financing, with participation from the Roche Venture Fund. Two Third Rock representatives, Neil Exter and Charles Homcy, joined the board. The announcement linked the money to expanding the team and relocating to the Bay Area by the end of 2010. There was capital, and there were people arriving with it. The board would change as the company changed. The financing terms make the organizational work visible beside the financial figure.
In August 2011, Sean McCarthy became chief executive, succeeding Stagliano. She was to join CytomX’s scientific advisory board and work as a consultant. Her first CEO chapter closed with a continuing scientific connection. The transition also gives the chronology an essential boundary: the co-founder who helped establish CytomX was its early chief executive, rather than the person leading it today. The succession announcement preserves that distinction.
One organization becomes two
The next appointment came quickly. Stagliano joined iPierian as CEO in September 2011. Two years later, the business announced a $30 million financing that would support iPierian and launch a separate company, True North Therapeutics. Its two research programs represented distinct opportunities. Each would have its own company. Stagliano would serve as chief executive of both. The September 2013 announcement describes the split and the shared leadership.
For a reader following her career, this is the point where a conventional ladder becomes a branching diagram. A new title does not simply replace the previous one. One organization creates another, and the responsibilities overlap. There is a practical elegance to the arrangement: two distinct programs receive two distinct corporate homes. There is also an excellent reason to keep a careful calendar.
In April 2014, Bristol-Myers Squibb acquired iPierian. The transaction carried a $175 million purchase price, with the possibility of another $550 million in development and regulatory milestones, plus future royalties. Three years later, Bioverativ completed its acquisition of True North. Its upfront consideration was $400 million plus assumed cash, with up to $425 million in additional milestone payments. The iPierian transaction and True North transaction were separate deals with separate conditions.
The distinction between upfront money and conditional payments is part of the story. The familiar $725 million and $825 million figures combine a purchase price with possible future milestones. Reading the terms closely gives a more useful picture of what changed hands. It also keeps the achievement in proportion: companies Stagliano led had reached acquisition agreements, with further value tied to what happened afterward.
“Be flexible and listen.”Nancy Stagliano · 2022
The people who turn up again
A career of successive companies can sound like a succession of fresh starts. Stagliano’s professional connections supply continuity. In 2022, she described working with investor Beth Seidenberg across three companies over fourteen years. Her appreciation was specific: Seidenberg anticipated difficulties, remembered details, and brought people into the conversation when a business needed help. These are ordinary actions with considerable consequences. Stagliano’s description of Seidenberg places the relationship in the day-to-day work of supporting an executive.
Another recurring colleague is Adam Rosenthal. Before founding Star Therapeutics and co-founding Electra, he worked as chief business officer at True North and in corporate development at iPierian. Stagliano now chairs the boards of Star and Electra. Their careers intersect across operating roles, acquisitions, and later ventures. The names in a company’s history can become the names in its next chapter. Electra’s leadership biographies show several of those connections in one place.
A new chair, and room for new leaders
Stagliano became Neuron23’s board chair in October 2018 and its CEO in October 2020. She continues in both roles. The company announced a $96.5 million Series D financing in June 2025, supported by a group that included existing investors Westlake Village BioPartners, SoftBank Vision Fund 2, Redmile, and Kleiner Perkins. The financing announcement records another substantial capital round in the career of an executive who has repeatedly worked between scientific teams and investors.
In January 2026, she added the executive chair role at Sundance Biosciences. Its board also includes Seidenberg, while Andrew Yost serves as CEO. Stagliano’s current responsibilities therefore span an operating position at Neuron23 and board leadership elsewhere. Sundance’s team page shows the new arrangement; her Electra biography dates the appointment.
Mentoring first-time CEOs and emerging entrepreneurs is another part of her work. It gives the earlier management learning curve a later counterpart. Having moved from the laboratory into leadership herself, she now spends time with people making their own transitions. The emphasis on mentoring appears in her 2026 university profile and in her current Neuron23 biography.
There is a life beyond the company names, too. Stagliano has a passion for horses, an interest she discussed in a 2022 podcast. It supplies a welcome change of subject after financing rounds and board appointments. Even an executive’s biography benefits from leaving the conference room occasionally. The conversation about horses offers that other side of her.
Her advice to prospective founders emphasizes flexibility and listening. She has recommended Adam Grant’s Think Again, a book about reconsidering one’s assumptions. That advice fits a career with several changes of discipline and several changes of company. The record begins with engineering degrees, passes through research and a small Santa Barbara startup, and arrives at the work of helping other people lead. Starting again has given her plenty of opportunities to learn.